Open access peer-reviewed Edited Volume

CRISPR Technology

Yuan-Chuan Chen

Jenteh Junior College of Medicine, Nursing and Management

Yuan-Chuan Chen completed his Ph.D. in Comparative Biochemistry at the University of California, Berkeley (UCB), USA. His studies are focusing on the discovery, production, application of biopharmaceuticals. Additionally, he is interested in basic research and human therapeutics using CRISPR/Cas9.


crRNA tracr RNA sgRNA PAM sequence Encoding Silencing Enhancing Modification Genetic Engineering Animal Model Delivery Tool CRISPR

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated (Cas) protein is a system originated from bacteria that confer resistance to plasmids or phages and provides an adaptive immunity for the host. CRISPR RNAs (crRNAs) are transcribed from CRISPR locuses. Transactivating crRNA (tracrRNA) is partially complementary to and pairs with a pre-crRNA to form an RNA duplex cleaved by RNase III and a crRNA/tracrRNA hybrid acts as a guide for the endonuclease Cas, which cleaves the invading DNA. Currently, it has been successfully used in genome editing such as silencing, enhancing, or modification of specific genes. Plasmids are constructed to express crRNA and tracrRNA together as single-guide RNAs (sgRNA). By the Cas proteins and a specifically designed sgRNA, the organism’s genome can be cleaved at most locations with the only limitation being the availability of an NGG protospacer adjacent motif (PAM) sequence in the targeting site. Efficient genome engineering has been performed in human cells, bacteria, yeasts, zebrafish, nematodes, plants, animals, etc. These findings and their implications may be discussed in the broadest context possible. Future research directions may also be highlighted. In this book, we will explore the development of CRISPR-Cas encoding and its application in basic research.

Publishing process

Book initiated and editor appointed

Date completed: March 30th 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: June 10th 2022

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register here

Approved chapters written in full and submitted

Deadline for full chapters: August 9th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 28th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 27th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Yuan-Chuan Chen

Jenteh Junior College of Medicine, Nursing and Management

Yuan-Chuan Chen completed his PhD in Comparative Biochemistry at the University of California, Berkeley (UCB), USA and had postdoctoral studies at the Taiwan Food and Drug Administration (TFDA). His research interests include Pharmacy/Pharmacology, Biochemistry, Microbiology/Virology, Cell/Molecule Biology, Biotechnology/Nanotechnology, Cell/Gene therapy and Policy/Regulation. He has participated in publishing many co-authored articles in peer-reviewed journals and book chapters in the fields of basic science, biomedicine, and related policy/regulation. He is now an assistant professor in Jenteh Junior College of Medicine, Nursing and Management, Taiwan. He is also an adjunct member in the biopharmaceutical division of Chinese Pharmacopoeia (Taiwan) Revising Committee (9th edition) and has reviewed many materials for Pharmacopoeia revising. His research is focusing on the discovery, production, application, perspectives and challenges of biopharmaceuticals. He is interested in basic research, the development of agricultural/industrial products and human therapeutics using the CRISPR/Cas9 system. Additionally, he is specialized in genomic studies including genomic analysis, gene function, and gene expression and control.

View profile

Book chapters authored 6

Books edited 2

Introducing your Author Service Manager

Mrs. Silvia Sabo

Ask a question

Book will be abstracted and indexed in